This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Wiersinga WM, Bartalena L (2002) Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 12:855–860
Gianoukakis AG, Smith TJ (2008) Recent insights into the pathogenesis and management of thyroid-associated oph-thalmopathy. Curr Opin Endocrinol Diabetes Obes 15:446–452
Feldon SE, Park DJ, O'Loughlin C W, et al (2005) Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 46:3913–3921
Smith TJ (2004) Novel aspects of orbital fibroblast pathology. J Endocrinol Invest 27:246–253
McLachlan SM, Nagayama Y, Rapoport B (2005) Insight into Graves' hyperthyroidism from animal models. Endocr Rev 26:800–832
Jacobson EM, Tomer Y (2007) The genetic basis of thyroid autoimmunity. Thyroid 17:949–961
Villadolid MC, Yokoyama N, Izumi M, et al (1995) Untreated Graves disease patients without clinical ophthal-mopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 80:2830–2833
Eckstein AK, Lax H, Losch C, et al (2007) Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 67:607–612
Bartley GB, Fatourechi V, Kadrmas EF, et al (1996) Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:426–434
Eckstein AK, Loesch C, Okundia H, et al (2009) Patients with euthyroid and primarily hypothyroid status have low TRAb levels and develop a tendentious milder and signifi-cantly more asymmetric Graves' Ophthalmopathy. Br J Ophthalmol in print
Khoo DH, Eng PH, Ho SC, et al (2000) Graves' ophthal-mopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 10:1093–1100
Bartley GB, Fatourechi V, Kadrmas EF, et al (1996) Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284–290
Wiersinga W, Kahaly G (2007) Graves's ophthalmopathy. A multidisciplinary approach. Karger
Wiersinga WM, Perros P, Kahaly GJ, et al (2006) Clinical assessment of patients with Graves orbitopathy: the European Group on Graves Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155:387–389
Hintschich C, Haritoglou C (2005) Full thickness eyelid transsection (blepharotomy) for upper eyelid lengthening in lid retraction associated with Graves disease. Br J Ophthalmol 89:413–416
Mourits M P, Prummel MF, Wiersinga WM, et al (1997) Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14
Terwee CB, Prummel MF, Gerding MN, et al (2005) Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 62:145–155
Mourits M P, Prummel MF, Wiersinga WM, et al (1994) Measuring eye movements in Graves ophthalmopathy. Ophthalmology 101:1341–1346
Eckstein AK, Plicht M, Lax H, et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470
Kahaly GJ (2004) Recent developments in Graves' ophthal-mopathy imaging. J Endocrinol Invest 27:254–258
Bartalena L, Baldeschi L, Dickinson A, et al (2008) Consensus statement of the European Group on Graves orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285
Perros P, Crombie AL, Kendall-Taylor P (1995) Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 42:45–50
Kahaly G (2007) Management of moderately severe Graves orbitopathy. In: Wiersinga WM, Kahaly GJ (eds) Graves orbitopathy: a multidiscplinary approach. Karger, Basel, pp 120–152
Kahaly GJ, Pitz S, Hommel G, et al (2005) Randomized, single blind trial of intravenous versus oral steroid mono-therapy in Graves orbitopathy. J Clin Endocrinol Metab 90:5234–5240
Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al (2000) Radiotherapy for Graves orbitopathy: randomised placebo-controlled study. Lancet 355:1505–1509
Prummel MF, Terwee CB, Gerding MN, et al (2004) A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmo-pathy. J Clin Endocrinol Metab 89:15–20
Bradley EA, Gower E W, Bradley DJ, et al (2008) Orbital radiation for graves ophthalmopathy: a report by the American academy of ophthalmology. Ophthalmology 115:398–409
Marcocci C, Bartalena L, Panicucci M, et al (1987) Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxf) 27:33–42
Marcocci C, Bartalena L, Tanda ML, et al (2001) Comparison of the eff ectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86:3562–3567
El Fassi D, Banga J P, Gilbert JA, et al (2009) Treatment of Graves disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130:252–258
Heemstra KA, Toes RE, Sepers J, et al (2008) Rituximab in relapsing Graves disease, a phase II study. Eur J Endocrinol 159:609–615
Salvi M, Vannucchi G, Campi I, et al (2007) Treatment of Graves disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156:33–40
Paridaens D, van den Bosch WA, van der Loos TL, et al (2005) The eff ect of etanercept on Graves' ophthalmopa-thy: a pilot study. Eye 19:1286–1289
Traisk F, Tallstedt L (2001) Thyroid associated ophthalmo-pathy: botulinum toxin A in the treatment of upper eyelid retraction–a pilot study. Acta Ophthalmol Scand 79:585–588
Baldeschi L (2008) Correction of lid retraction and exophthalmos. Dev Ophthalmol 41:103–126
Garrity JA, Bahn RS (2006) Pathogenesis of graves oph-thalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 142:147–153
Mourits M P, Bijl HM, Baldeschi L, et al (2008) Outcome of orbital decompression for disfiguring proptosis in patients with Graves orbitopathy using various surgical procedures. Br J Ophthalmol
Esser J, Eckstein A (1999) Ocular muscle and eyelid surgery in thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 107(Suppl 5):S214–S221
Eckstein A, Holdt M, Johnson KTM, et al (2008) Tendon elongation: a new surgical technique for large convergent squint af er three wall orbital decompression in thyroid associated ophthalmopathy. ESA proceedings
Eckstein A, Schulz S, Esser J (2004) Is combined surgical correction of horizontal and vertical squint of value in graves' ophthalmopathy? Klin Monatsbl Augenheilkd 221:769–775
Krzizok T, Efinger K, Kaufmann H (1993) Dosierbarkeit von Augenmuskeloperationen bei endokriner Orbitopathie. Z prakt Augenheilk 14:273–279
Schittkowski M, Fichter N, Guthoff R (2004) Strabismus surgery in Graves disease–dose-eff ect relationships and functional results. Klin Monatsbl Augenheilkd 221:941–947
Neoh C, Eckstein A (2007) Eyelid surgery. In: Wiersinga WM, Kahaly GJ (eds) Graves orbitopathy: a multidisc-plinary approach. Karger, Basel, pp 188–198
Tallstedt L, Lundell G, Torring O, et al (1992) Occurrence of ophthalmopathy af er treatment for Graves' hyperthy-roidism. The thyroid study group. N Engl J Med 326:1733–1738
Marcocci C, Bruno-Bossio G, Manetti L, et al (1999) The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 51:503–508
Dralle H, Sekulla C (2004) Morbidity af er subtotal and total thyroidectomy in patients with Graves disease: the basis for decision-making regarding surgical indication and extent of resection. Z Arztl Fortbild Qualitatssich 98(Suppl 5):45–53
Bartalena L, Marcocci C, Bogazzi F, et al (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73–78
Perros P, Kendall-Taylor P, Neoh C, et al (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab 90:5321–5323
Carella C, Mazziotti G, Sorvillo F, et al (2006) Serum thy-rotropin receptor antibodies concentrations in patients with Graves disease before, at the end of methimazole treatment, and af er drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16:295–302
Schott M, Morgenthaler NG, Fritzen R, et al (2004) Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves disease. Horm Metab Res 36:92–96
Orgiazzi J, Madec AM (2002) Reduction of the risk of relapse af er withdrawal of medical therapy for Graves disease. Thyroid 12:849–853
Khoo DH, Ho SC, Seah LL, et al (1999) The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves disease iden-tifies a group at markedly increased risk of ophthalmopathy. Thyroid 9:1175–1180
Gerding MN, van der Meer J W, Broenink M, et al (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 52:267–271
Noh JY, Hamada N, Inoue Y, et al (2000) Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves disease. Thyroid 10:809–813
Eckstein AK, Plicht M, Lax H, et al (2004) Clinical results of anti-inflammatory therapy in Graves' ophthalmopa-thy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 61:612–618
Eckstein AK, Plicht M, Lax H, et al (2006) TSH-receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91(9):3464–3470
Pfeilschifer J, Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45:477–481
Eckstein A, Quadbeck B, Mueller G, et al (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87:773–776
Cawood TJ, Moriarty P, O'Farrelly C, et al (2007) Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 92:59–64
Brix TH, Kyvik KO, Christensen K, et al (2001) Evidence for a major role of heredity in Graves disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 86:930–934
Manji N, Carr-Smith JD, Boelaert K, et al (2006) Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 91:4873–4880
Ban Y, Tomer Y (2005) Genetic susceptibility in thyroid autoimmunity. Pediatr Endocrinol Rev 3:20–32
Aust G, Krohn K, Morgenthaler NG, et al (2006) Graves disease and Hashimoto's thyroiditis in monozygotic twins: case study as well as transcriptomic and immunohistologi-cal analysis of thyroid tissues. Eur J Endocrinol 154:13–20
Eckstein A, Loesch C, Glowacka D, et al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetric Graves ophthalmopathy. Br J Ophthalmol 93:1052–1056
Krassas GE, Gogakos A (2006) Thyroid-associated oph-thalmopathy in juvenile Graves disease–clinical, endocrine and therapeutic aspects. J Pediatr Endocrinol Metab 19:1193–1206
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Eckstein, A., Esser, J. (2010). Modern Treatment Concepts in Graves Disease. In: Lorenz, B., Brodsky, M.C. (eds) Pediatric Ophthalmology, Neuro-Ophthalmology, Genetics. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85851-5_16
Download citation
DOI: https://doi.org/10.1007/978-3-540-85851-5_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-85850-8
Online ISBN: 978-3-540-85851-5
eBook Packages: MedicineMedicine (R0)